

Nicholas Turner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1886466/nicholas-turner-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16
papers

1,911
citations

8
h-index

23
g-index

23
ext. papers

2,251
ext. citations

11.2
avg, IF

5.38
L-index

#	Paper	IF	Citations
16	Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC). <i>Cancer Research</i> , 2022 , 82, P5-16-11-P5-16-11	10.1	
15	Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study. <i>Cancer Research</i> , 2022 , 82, P1-18-35-P1-18-35	10.1	0
14	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	6
13	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.. <i>Nature Cancer</i> , 2021 , 2, 1321-1337	15.4	17
12	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.. <i>Nature Cancer</i> , 2021 , 2, 1321-1337	15.4	24
11	Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. <i>Cancer Treatment and Research Communications</i> , 2020 , 24, 100188	2	6
10	Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative		10
9	Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010) 2020 ,		7
8	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) 2020 ,		19
7	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. <i>European Radiology</i> , 2020 , 30, 6702-6708	8	6
6	Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 101-111	4.4	13
5	Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. <i>Journal of Clinical Oncology</i> , 2019 , 37, 689-692	2.2	20
4	Reply to J.A. Sparano et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1842	2.2	
3	Endocrine-based therapy versus chemotherapy in advanced breast cancer. <i>Lancet Oncology</i> , 2019 , 20, 1632-1633	21.7	3
2	Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer. <i>Cancer Discovery</i> , 2017 , 7, 1368-1370	17.0	10
1	Fibroblast growth factor signalling: from development to cancer. <i>Nature Reviews Cancer</i> , 2010 , 10, 116-29	31.3	1768